company background image
DXCM logo

DexCom NasdaqGS:DXCM Stock Report

Last Price

US$80.04

Market Cap

US$29.6b

7D

3.7%

1Y

-34.5%

Updated

20 Dec, 2024

Data

Company Financials +

DXCM Stock Overview

A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details

DXCM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

DexCom, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for DexCom
Historical stock prices
Current Share PriceUS$80.04
52 Week HighUS$142.00
52 Week LowUS$62.34
Beta1.13
1 Month Change6.38%
3 Month Change13.64%
1 Year Change-34.48%
3 Year Change-44.03%
5 Year Change46.79%
Change since IPO2,627.09%

Recent News & Updates

Recent updates

DexCom: Brighter 2025 From Stelo Ramp

Dec 10

Is It Too Late To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Dec 05
Is It Too Late To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Nov 08
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

Oct 21
DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Sep 30
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Sep 16
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Shareholder Returns

DXCMUS Medical EquipmentUS Market
7D3.7%-1.5%-2.4%
1Y-34.5%10.1%23.3%

Return vs Industry: DXCM underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: DXCM underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is DXCM's price volatile compared to industry and market?
DXCM volatility
DXCM Average Weekly Movement4.8%
Medical Equipment Industry Average Movement7.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: DXCM has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DXCM's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19999,550Kevin Sayerwww.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

DexCom, Inc. Fundamentals Summary

How do DexCom's earnings and revenue compare to its market cap?
DXCM fundamental statistics
Market capUS$29.61b
Earnings (TTM)US$680.80m
Revenue (TTM)US$3.95b

45.9x

P/E Ratio

7.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXCM income statement (TTM)
RevenueUS$3.95b
Cost of RevenueUS$1.52b
Gross ProfitUS$2.44b
Other ExpensesUS$1.76b
EarningsUS$680.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.74
Gross Margin61.68%
Net Profit Margin17.22%
Debt/Equity Ratio123.3%

How did DXCM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 04:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DexCom, Inc. is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
Anand VankawalaAvondale Partners
null nullBaird